Clinical Trials Logo

Actinic Keratosis clinical trials

View clinical trials related to Actinic Keratosis.

Filter by:

NCT ID: NCT04779255 Not yet recruiting - Pain Clinical Trials

Pain Management During a Photodynamic Therapy Session on the Vertex for Actinic Keratosis: Tumescent Anesthesia Interest

ANTUKA
Start date: May 2021
Phase: N/A
Study type: Interventional

This study focus on the efficacity of tumescent anesthesia in pain management during a photodynamic therapy on the vertex for treatment of actinic keratosis. To do this we carried out a prospective, randomized, controlled, open-ended study. Our aim is to show a 40% reduction in pain during photodynamic therapy session compared to a conventionally used analgesic method (paracetamol + cold water)

NCT ID: NCT04552327 Recruiting - Actinic Keratosis Clinical Trials

5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis

KOHDIAK
Start date: October 14, 2020
Phase: Phase 3
Study type: Interventional

The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical device) versus placebo and investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is performed in accordance with both the laws in force for clinical trials with medical devices and those with medicinal products.

NCT ID: NCT04396184 Recruiting - Actinic Keratosis Clinical Trials

Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy#ALA-PDT) to a conventional regimen for treatment of Actinic Keratosis. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.

NCT ID: NCT04202445 Completed - Actinic Keratosis Clinical Trials

TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction

MIKADO
Start date: April 2014
Phase:
Study type: Observational

This is an observational longitudinal study, prospective, multicenter, performed in metropolitan France, on a representative sample of dermatologists. Data will be collected by physicians during 2 or 3 visits (according to their usual practice), from the patient file, questioning and clinical examination performed during these visits. Data about the patient's perception (satisfaction, perception of local skin reactions, quality of life) will be collected directly by the patient using self-administered questionnaires at inclusion visit, day 7 and 2 months later.

NCT ID: NCT04140292 Active, not recruiting - Actinic Keratosis Clinical Trials

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Start date: November 11, 2019
Phase: Phase 2
Study type: Interventional

This study is open to individuals with Actinic Keratoses (skin lesions that have the potential to turn into skin cancer), who are receiving photodynamic therapy (PDT) as part of their clinical care. The purpose of this study is to test and demonstrate that vitamin D pre-treatment can enhance PDT efficacy in the treatment of Actinic Keratoses. Participants will be asked to take vitamin D supplements prior to their standard of care PDT treatment. Participation in the research will last about 3-4 months.

NCT ID: NCT03914417 Completed - Actinic Keratosis Clinical Trials

Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The study team had plans to treat approximately 30 subjects. Each subject that had qualified had at least 4-8 visible AKs on the face and/or scalp. At Day 0, one Actinic Keratosis (AK) in the treatment area had been biopsied via a 3 mm punch. The tissue collected was sent to pathology for confirmatory diagnosis as well as genomic analysis. The remaining AKs had been identified, photographed, and documented on a transparency. One of the remaining AKs was designated as the target lesion. The patient returned to the clinic in 7 days (+/- 3) for suture removal. Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14). At week 14, a biopsy via a 3 mm punch was done of the target lesion. Yet, if the target lesion was no longer present, a biopsy was done at the site where the lesion was previously located.

NCT ID: NCT03805737 Recruiting - Actinic Keratosis Clinical Trials

Indoor Daylight Photo Dynamic Therapy for Actinic Keratosis

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to understand better if indoor daylight Photo Dynamic Therapy (PDT) can provide effective lesion clearing versus conventional red lamp light therapy.

NCT ID: NCT03731988 Completed - Actinic Keratosis Clinical Trials

Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

Erbium:yttrium aluminum garnet (Er:YAG) ablative fractional laser-assisted photodynamic therapy (AFL-PDT) has shown significant benefit for the treatment of actinic keratosis(AK). Er:YAG ablative fractional laser ablates the epidermis and dermis without significant thermal injury, creating microscopic ablation zones (MAZ) in the portion of the skin that the laser is applied to. The formed MAZ depends on the laser parameters such as laser depth, laser density and laser passes, which affect the treatment outcome.

NCT ID: NCT03684772 Recruiting - Actinic Keratosis Clinical Trials

Topical Ionic Contra-Viral Therapy in Actinic Keratosis

Start date: October 22, 2018
Phase: Phase 2
Study type: Interventional

To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK.

NCT ID: NCT03643744 Recruiting - Actinic Keratosis Clinical Trials

Photodynamic Therapy-Induced Immune Modulation: Part III

Start date: April 1, 2019
Phase: Phase 1
Study type: Interventional

This study is designed as a double-blinded proof of concept of feasibility study to define if the immunosuppression associated with photodynamic therapy (PDT) can be blocked by treatment with cyclo-oxygenase-2 (COX-2) inhibitor celecoxib in comparison to placebo. PDT consists of application of the photosensitizer 5-aminolevulinic acid followed by treatment with a blue light. PDT is used to treat pre-cancerous actinic keratosis on large areas of skin. These studies are a continuation of ongoing studies that indicate that the lipid mediator platelet-activating factor (PAF) is generated in skin following PDT, and that PDT suppresses the immune system. It is hypothesized that PDT-generated PAF results in the immunosuppression associated with PDT. Therefore, it is proposed that a treatment to block that immunosuppression could protect the patient undergoing PDT. Blockers of the PAF system are not currently commercially available. However research studies done at Wright State University using mice indicate that PAF- and PDT-induced immunosuppression is blocked by treatment with COX-2 inhibitors. This study is conducted as a proof of concept. Study length and visit for subjects with actinic keratoses: The first part of the study is completed in 12 days then there are follow up visits at 6 and 12 months. There are a total of 6 separate visits to the research office. Study length and visit for control subjects: The study is completed in 10 days. There are a total of 4 separate visits to the research office.